Latest News
P95 and LatinaBA enter a strategic partnership to propel vaccine research in Latin America
P95 and LatinaBA are pleased to announce their strategic partnership, aimed at propelling vaccine and infectious disease research in Latin America.
P95 and LatinaBA enter a strategic partnership to propel vaccine research in Latin America
P95 and LatinaBA are pleased to announce their strategic partnership, aimed at propelling vaccine and infectious disease research in Latin America.
COVID-19 vaccine effectiveness study against JN.1 variant using id.DRIVE platform
Background Prior studies have reported lower effectiveness of XBB.1.5-adapted vaccines against hospitalization related to the COVID-19 Omicron JN.1 variant than the XBB variant. This study evaluated the effectiveness and durability of the BNT162b2 XBB.1.5-adapted...
P95 At World Vaccine Congress Europe 2024
This October, the P95 team attended and exhibited at Europe's largest vaccine event, the World Vaccine Congress Europe 2024 held in Barcelona! As a global leading CRO specializing in vaccines and infectious diseases, P95 had a prime location with one of the most...
P95 and LatinaBA enter a strategic partnership to propel vaccine research in Latin America
P95 and LatinaBA are pleased to announce their strategic partnership, aimed at propelling vaccine and infectious disease research in Latin America.
COVID-19 vaccine effectiveness study against JN.1 variant using id.DRIVE platform
Background Prior studies have reported lower effectiveness of XBB.1.5-adapted vaccines against hospitalization related to the COVID-19 Omicron JN.1 variant than the XBB variant. This study evaluated the effectiveness and durability of the BNT162b2 XBB.1.5-adapted...
Protocol development: Observational study EAGLE
Abstract Background: Immunocompromised individuals are known to respond inadequately to SARS-CoV-2 vaccines, placing them at high risk of severe or fatal COVID-19. Thus, immunocompromised individuals and their caregivers may still practice varying degrees of social or...
Latest Press
P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services
P95, a leading global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases, is excited to announce the acquisition of Assign DMB.
P95 and LatinaBA enter a strategic partnership to propel vaccine research in Latin America
P95 and LatinaBA are pleased to announce their strategic partnership, aimed at propelling vaccine and infectious disease research in Latin America.
P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services
P95, a leading global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases, is excited to announce the acquisition of Assign DMB.
P95 Acquires 4Clinics to Expand Global CRO Services, Strengthen Position as Market Leader
P95 BV, is excited to announce the strategic acquisition of 4Clinics, a Contract Research Organization providing Data Management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies.
P95 Expands its Global Presence with a New USA Office
P95 has opened its first office in the USA. Based in the Research Triangle Park in North Carolina, the largest research park in the USA, this expansion underlines P95s commitment to delivering high-quality research solutions to our clients and partners across the globe.
P95 Company News
View All
P95 Transforming Exercise into Charitable Impact
At P95, we believe in the power of movement – not just as a means to personal health, but as a catalyst for global change. Our Strava group, an initiative that promotes health and fitness within the team, has successfully translated the time logged over the last year into substantial donations for three charities that make a real difference.
Laurence De Moerlooze Joins P95 as Chief Medical Officer
P95 BV, an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO).
Celebrating P95’s Anniversary: From our Humble Beginnings to a Global Full-Service CRO
As we approach our 13th anniversary on June 16, we pause to celebrate important milestones and extend our deepest gratitude to our staff, partners and clients who have been part of our growth journey!
P95’s Journey From Epidemiology Consulting to Comprehensive CRO
In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).
Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.
P95 welcomes John O’Brien as Chief Business Officer
We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.
Events News
View All
P95 At Vaccine World Asia Congress
P95 successfully exhibited at the Vaccine World Asia Congress 2024, held on 6-7 November in Bangkok, Thailand. The...
P95 At World Vaccine Congress Europe 2024
This October, the P95 team attended and exhibited at Europe's largest vaccine event, the World Vaccine Congress Europe 2024 held in Barcelona! As a global leading CRO specializing in vaccines and infectious diseases, P95 had a prime location with one of the most...
P95 Webinar Explores Insights to Conducting Clinical Trials in Africa
Join P95 for its webinar on Insights to conducting clinical trials in Africa, on 5 November.
P95 Attends National Clinical Research Network Thailand 2023
P95 took center stage at a pivotal event in Thailand’s clinical research scene—the National Clinical Research Network (NCRN) Conference 2023.
P95 Attends Infectology Congress in Buenos Aires
Last week, P95 attended for the first time, the Congreso de Infectología 2023 organized by Asociación Panamericana de Infectología (API) and Sociedad Argentina de Infectología (SADI), which took place in Buenos Aires, Argentina.
This congress gathered renowned experts from the field of infectology, who shared lessons learnt and debated the most pressing and current topics on this topic.
More about the congress: https://www.congresosadi.com/
P95 is a full-service Contract Research Organization (CRO) specializing in clinical trials, epidemiology, and real-world evidence, for vaccines and infectious diseases.